Lightlake Therapeutics has announced today that it has hired former Mundipharma Head of Medical Affairs for New Products Arvind Agrawal as Executive VP, Medical Affairs, effective January 2015. Agrawal has also held Medical Affairs positions at Reckitt Benckiser and AstraZeneca.
In December 2014, Lightlake announced that it had licensed its intranasal naloxone product for opioid overdose reversal to Adapt Pharma for development. The company is also developing intranasal naloxone for binge eating disorder and bulimia nervosa.
Lightlake CEO Roger Crystal said, “Arvind brings an extensive and impressive background in medical and clinical affairs, having worked with key global regulatory authorities. He joins us at an ideal time to lead our medical and clinical affairs as we advance our clinical trials and move our product pipeline forward now that we have partnered with Adapt Pharma Limited on our opioid overdose reversal product.”
Read the Lightlake press release.
